POPULARITY
46 episodes with p4a
2 episodes with p4a
2 episodes with p4a
2 episodes with p4a
6 episodes with p4a
2 episodes with p4a
Discover how artificial intelligence is transforming the future of rare disease research in the latest episode of Let's Talk Rare, the official podcast from Partners4Access (P4A). Join us as we sit down with Ilya Burkov, AI expert at Nebius to explore how cutting-edge machine learning tools are accelerating the discovery, diagnosis, and development of treatments for rare conditions. With over 300 million people affected by rare diseases worldwide, the need for faster, smarter solutions has never been greater. Ilya sheds light on the real-world applications of AI in identifying new genetic links, optimizing clinical trial data, and personalising care pathways. Whether you're a biotech professional, healthcare provider, or advocate, this episode offers critical insights into how AI is reshaping the rare disease landscape. Tune in now to understand the promises, challenges, and future possibilities of AI in rare disease development—only on Let's Talk Rare, brought to you by P4A.
Dive into P4A's annual appraisal of the year ahead. In this episode of Let's Talk Rare we examine the most important trends as identified and voted for by the P4A team. Ranging from Donald Trump's tariff impact on EU's ability to price orphan drugs to the change of mindset in HTA bodies to include patient experience data in their decision making calculations. Join Owen & Georgie, along with Sophie Schmitz and Pina Haberl for a wide ranging and dynamic discussion on the year ahead.
Welcome to this month's episode of the P4A Let's Talk Rare podcast by Partners4Acess. Today, Georgie and Owen are joined by their colleagues Aurelija Luko, the CFO, and Darren Callanan, the Global Digital Lead at Partners4Access. Join them as they discuss the recent job cuts in the pharma and biotech industry and the reasons behind them. Aurelia explains that redundancies are not limited to the pharma industry and are influenced by factors like mergers, expiring patents, and macroeconomic instability. Darren adds that high drug development costs and pricing pressures also contribute to layoffs. However, he suggests that companies can use digital tools to enhance efficiency and innovation to address industry challenges. They also discuss a digital launch platform and a social listening tool created by Partners4Access. Aurelia highlights that companies are looking to increase shareholder value and reduce costs. Darren adds that thanks to the high cost of drug development and downward pressure on prices, companies are forced to narrow their focus and compete in the same space, leading to layoffs. The conversation then shifts to discuss the digital launch platform created by Partners for Access. Darren explains that the platform streamlines the access and utilization of launch materials, ensuring that affiliates have access to the most up-to-date and compliant versions. This helps overcome the challenge of inconsistent distribution and saves time for the teams. Darren also mentions another tool called RarePulse, a social listening platform. This tool collects and analyzes data from social media and other sources to provide insights on key opinion leaders, unmet patient needs, and other relevant topics. He emphasizes that social media listening allows for a broader understanding of patient experiences and can help shape primary research and launch strategies. Aurelija Luko Bio: Aurelija's work at P4A includes overseeing all accounting activities, from managing financial risk to setting budgets. Also, to ensure smooth day-to-day finance operations within the business. Aurelija is a Chartered Accountant with 10+ years of experience; she holds an MSc in Financial Economics from the University of Exeter and a BSc in the same field. Before P4A, she worked for small start-ups and big listed companies in healthcare, consulting, and property industries. She is a problem solver who can adapt well to new situations and review and improve the internal controls within the organization. Darren Callanan Bio: Darren Callanan is the Global Digital Lead at Partners4Access. He works in a specialist consultancy team to develop digital solutions addressing healthcare delivery barriers. Darren holds a master's degree in Biotechnology and Business Management from the University of Warwick and an honors degree in Physiology from the National University of Ireland, Galway. His expertise includes strong communication and interpersonal skills, supported by a robust scientific background across various therapeutic areas. Previously, he worked at S3 Connected Health. Episode Resources: Aurelija Luko on LinkedIn Darren Callanan on LinkedIn Owen Bryant on LinkedIn Georgina Rack on LinkedIn Partners4Access Website P4A Let's Talk Rare podcast on Apple Podcasts
Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Project for Awesome 2024: Make a short video for an EA charity!, published by EA ProjectForAwesome on January 31, 2024 on The Effective Altruism Forum. Project for Awesome (P4A) is a charitable initiative running February 16th-18th this year (2024), and videos must be submitted by 11:59am EST on Tuesday, February 13th. This is a good opportunity to raise money for EA charities and promote EA and EA charities to a wider audience. In the last years, winning charities got between $14,000 and $38,000 each. Videos don't need to be professional! In short, People make short 1-4 min videos supporting charities, upload them on Youtube and submit them to the P4A website by 11:59am EST on Tuesday, February 13th. The videos must be new videos specifically for this year's P4A and should mention P4A. People vote on the videos on the weekend, February 16th-18th. Money raised during the Project for Awesome is split, with 50% going to Save the Children and Partners in Health, and 50% going to charities voted on by the community. One more video for a charity lets everyone vote one more time for that charity. This year, we want to support seven EA charities: Against Malaria Foundation, GiveDirectly, The Humane League, Good Food Institute, ProVeg International, GiveWell and Fish Welfare Initiative. Please consider making a short video for one (or more) of these charities! You will help us to coordinate if you sign up here. Please join the Facebook group, EA Project 4 Awesome 2024! In 2017, we secured a $50,000 donation for AMF, GiveDirectly and SENS. In 2018 GiveDirectly, The Good Food Institute and AMF all received $25,000. In 2020, seven out of eight of the charities we coordinated around have won ~$27,000 each, for a total that year of ~$189,700! In 2022, 3 out of 11 supported charities won. Last year, The Good Food Institute got ~$37,000. Here are some resources: Project for Awesome website A document with infos, resources and instructions http://www.projectforawesome.com/graphics How to Make a P4A video in 20 Minutes or Less Slides for a P4A video planning event from 2021 Video guidelines from the P4A FAQ: Your video must be made specifically for this year's P4A. So, you must mention Project for Awesome in the video itself, and it should have been created recently. You should put reasonable effort into making sure any information you include in your video is accurate, from anecdotal examples to statistics. There's a lot of misinformation on the internet, so we want to make sure that P4A videos are providing thoughtful, accurate context about the work that organizations are doing in the world. Try not to make your video too long. People are going to be watching a ton of videos during P4A, and no one wants to sit through a rambly, unedited vlog for ten minutes. Keep your video short and to the point so that people will watch the whole thing and learn all about your cause. A good length to aim for is 2-4 minutes, unless you have such compelling content that it just needs to be longer. Try not to spend too much time explaining what the Project for Awesome is. Most people watching your video will already know, so just mentioning it briefly and directing people to the website is plenty. An explanation in the description as well as a link to projectforawesome.com is also a great addition so people who stumble across your video can learn more about us. Similarly, try not to spend too much time promoting your own channel in your video. One or two sentences is fine to explain the type of videos you usually make if they're different from what you're doing for your P4A video, but much more than that and it just looks like you're using the P4A to help promote yourself, which isn't what this is all about. Please include a content warning at the beginning of your video if you're discussing sensit...
Hello and welcome to this special episode of Let's Talk Rare: The Life Science Podcast as we celebrate 5 years of bringing you the podcast that is now the number one life science podcast across all platforms. We at Partners 4 Access want to thank every single one of our 35,000 subscribers and all the guests who have graced the podcast from the bottom of our hearts, we would not have gotten here without you. A special episode calls for special guests, and joining us today are our in-house expert and Managing Partner at P4A, Sophie Schmitz, our host from 2018-2021, Aparna Krishnan, and Prasan Subedi, Access Strategy Team Lead at Pfizer. Together, we walk down memory lane and relive the high points and challenges of the past five years, and share insights on rare diseases and cell and gene therapies. Aparna Krishnan Bio: Aparna has over 10 years of experience in the pharmaceutical and healthcare industry. As part of the senior leadership team, her primary focus is on strategic corporate engagement, legal, financial operations, and human resources. She has previously worked as Manager of Life Sciences at IHS Markit and as Consultant at Parexel's Commercialization unit, among others specializing in market access, pricing, and reimbursement. Sophie Schmitz Bio: Sophie is the managing partner at Partners 4 Access, a company that believes in a sustainable rare disease world, which means helping our clients unlock the true opportunity of orphan drugs and ATMPs. Her 20+ year career spans various disease areas and medical devices, successfully supporting the strategy development and operationalization for orphan drugs. She brings a wealth of commercial and access experience across orphan and cell and gene therapies to the benefit of clients. She plays an active role in advising clients on price and market access strategies, with the ultimate goal of optimizing fair access for all stakeholders in rare diseases.
Is the P4A/ P4P relevant? What use cases is it being used? Will DJI continue to support it? Today's episode is brought to you by Drone U In-person Events. If you're looking to enhance your flight skills (and who among us doesn't need to enhance our flight skills), we are hosting our last in-person mapping training in November in beautiful Colorado. This is our three-day boot camp plus one-day Flight Mastery Training. We will be introducing and flying a variety of data acquisition types followed by discussion and instruction on how to process the acquired data. From Pix4d Mapper to Pix4d React, to Drone Deploy and Optelos. Students will go through a total of 7 exercises to master the workflow for various deliverables. The goal is to map and build models of this training's location. Join us today !! On today's show we discuss P4P, P4A, the Mavic3Pro for 3D Modeling and use cases for these drones. Our question for today is from Mike who would like to know if the P4P is still relevant in the industry. Thanks for the question Mike, we start off our discussion about the argument between professional drones, consumer drones and enterprise drones. We discuss budgeting, use cases and 3D modeling software and drones and new company along with the many technical specifications of these drones and their use cases that pilots should know. Mike also wanted to know about heating issues and we answer ways to address the heating issues. Tune in today to learn more about getting the best bang for your buck and how to effectively chose and purchase your drone. Get Your Biggest and Most Common Drone Certificate Questions Answered by Downloading this FREE Part 107 PDF Make sure to get yourself the all-new Drone U landing pad! Get your questions answered: https://thedroneu.com/. If you enjoy the show, the #1 thing you can do to help us out is to subscribe to it on iTunes. Can we ask you to do that for us real quick? While you're there, leave us a 5-star review, if you're inclined to do so. Thanks! https://itunes.apple.com/us/podcast/ask-drone-u/id967352832. Become a Drone U Member. Access to over 30 courses, great resources, and our incredible community. Follow Us Site – https://thedroneu.com/ Facebook – https://www.facebook.com/droneu Instagram – https://instagram.com/thedroneu/ Twitter – https://twitter.com/thedroneu YouTube – https://www.youtube.com/c/droneu Timestamps: [01:55] Is the P4P/P4A still relevant in the industry? [02:55] Today's question from Mike on P4A, P4P and heating issues [06:07] Using the Mavic3Pro for 3D Modeling [10:11] Are P4A still being used? And why?
P4A are joined by Xortx Therapeutics' CEO, Dr Allen Davidoff, as he discusses the journey from early development to potential launch for their novel therapy XRX-008 to treat patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Allen discusses the company vision for developing novel therapies for rare progressive kidney disorders, and tells us about the launch journey for their main therapeutic candidate for AKPKD. How they managed to complete enrolment for late phase study in record time by engaging with patients and advocacy groups early, to really understand the patient journey and how the disease affects their quality of life. This helped to shape the clinical trial design by truly putting the patients at the forefront of all decisions and to ensure they were involved at all stages of the process. Bio: Dr. Allen W. Davidoff, Ph.D. (15 years drug development experience ), Currently President and CEO of XORTX Therapeutics Inc (2013- ), Formerly, Chief Scientific Officer, VP Product Development and co-founder of Stem Cell Therapeutics Corp (Trillium Therapeutics- TRIL: NASDAQ) (7 yrs). Prior to Stem Cell Therapeutics Corp., Senior Scientist and Head of Pharmacology at Cardiome Pharma Corp. Dr. Davidoff has 12 + years of therapeutic drug development experience with a focus on clinical and regulatory developmental affairs, in the US, Canada, Germany, Denmark, and India. Senior management and leadership experience includes pharmaceutical non-clinical and clinical R&D including 2 investigational new drug (“IND”) applications or supplemental IND's, 2 phase I studies (4 multi-country), 7 phase II studies, and 1 NDA. Dr Allen Davidoff: https://www.linkedin.com/in/allen-davidoff-9a80968/ XORTX Therapeutics XORTX Therapeutics, Inc. is a drug based biotechnology company primarily focused on orphan disease indications which have aberrant purine metabolism and frequently high serum uric acid imbalance. Our focus on developing kidney therapies also includes therapeutics programs for large markets such as diabetic nephropathy and acute kidney injury associated with respiratory virus infections such as SARS-CoV-2. We possess patents and patent applications that may include U.S. and international rights regarding the development of uric acid-lowering agents for the treatment of hypertension, insulin resistance, diabetes, metabolic syndrome, and kidney injury. XORTX Therapeutics: https://www.xortx.com/
P4A host a special episode live from World Evidence, Pricing & Access Conference 2023 in Amsterdam. Join Georgie & Owen hosting live from World EPA Conference 2023. We will be bringing you speaker interviews, giving a flavour of the atmosphere and discussing some of the trends & key takeaways that came out of the conference. Max Rex: LinkedIn: https://www.linkedin.com/in/max-rex-7a364789/ Stefaan Friers: Takeda: https://www.takeda.com/ LinkedIn: https://www.linkedin.com/in/stefaanfiers/ Juliette Sinclair Spence: LinkedIn: https://www.linkedin.com/in/juliettevss/ Website: https://akeyefoundation.com/ Support Group: https://www.facebook.com/groups/acanthamoebakeratitissupportgroup Donate: https://akeyefoundation.com/donation/ Youtube video sharing my story: https://youtu.be/l35c4CF9DwQ Jelle Kleijn: Website: https://www.sifigroup.com/ LinkedIn: https://www.linkedin.com/in/jelle-kleijn-b6bbb520/
Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Project for Awesome 2023: Vote for videos of EA charities!, published by EA ProjectForAwesome on February 16, 2023 on The Effective Altruism Forum. Project for Awesome (P4A) is a yearly charity video contest running this weekend in 2023. Voting will start Friday, February 17th, 12:00pm EST and is open until February 19th, 11:59am EST. The charities with the most votes, the total across all their videos, win money. In the last years, this was between $14,000 and $32,000 per charity. This is a good opportunity to raise money for EA charities with just a few clicks (~5 minutes). Please ask your friends and EA group members to vote for ALL the videos for EA charities! A sample text message and a voting instruction is below. Sample text message: Hey! Not sure if you know, but every year Hank and John Green organize the Project For Awesome, which raises money for charities. All you have to do is click “Vote” on a bunch of videos and you could potentially help thousands of dollars go to highly effective charities. Would you be willing to help out? If they reply yes: Great! Here are the videos of the charities we're promoting. You can vote for all of the videos. Without watching videos, it will just take a few minutes. (insert the instructions or just the links) Voting instruction with links: 1. Invite your friends to vote, too! 2. Open one of the following links, then open one video first and do the CAPTCHA before opening the other videos of that charity in new tabs. Vote for ALL videos of that charity. 3. Repeat step 2 for all charities listed below. Vote for ALL videos for each of these EA charities. You can see that you voted for a video by the grayed out "Voted" button. In the end, P4A will sum up all votes for all videos of one charity. In total there are several videos for our supported EA charities but it only takes a few clicks (if you do not want to watch the videos) and it's really worth it. Supported EA charities:Animal Advocacy Africa: Ethics: Society: Top Charities Fund: Food Institute: Humane League: Animal Initiative: Other EA(-related) charities:International Campaign to Abolish Nuclear Weapons (ICAN): Against Malaria Foundation: Air Task Force:: Means No Worldwide: Global Fund: Please also join our Facebook group, EA Project 4 Awesome 2023, and our Facebook event for this year's voting! Thank you very much! Thanks for listening. To help us out with The Nonlinear Library or to learn more, please visit nonlinear.org.
The P4A team have hand-picked trends to look out for in 2023. This episode we are joined by special guest Neil Grubert who will be discussing the topics in further detail, alongside our P4A experts, Shrishti & Jodie. The topics covered are: EU Pharmaceutical Strategy, OMP Legislation, Joint HTA Assessments - cross-country HTA cooperation, Expansion of CAR-T & Hospital Exemptions across Europe and finally the Patient - Putting patients at the forefront of drug developers. Neil Grubert Bio: Neil has worked in Industry for over 20 years starting at Decision Resources as a researcher in 1997 and leaving as Vice President of Global Market Access Insights in 2013. Currently he is an independent MA consultant and has been doing this for the last 8 years. LinkedIn: https://www.linkedin.com/in/neil-grubert/ Hosts: Georgie Rack & Owen Bryant P4A Speakers: Srishti Gupta, Senior Consultant & Jodie Lyons, Analyst Produced by: Operations
Did you miss the World Orphan Drug Congress Europe 2022, held in Sitges, Barcelona in November? If you did, don't worry P4A have you covered! This month's special podcast was part recorded live at the conference and part recorded back in London with members of the team that attended! We will be speaking to a few presenters & sponsors to discuss their presentations, key learnings and their personal highlights from the conference. Also the P4A team will be talking about our favourite sessions and the key takeaways from the conference. Special thanks to our guests for their insights and learnings throughout the podcast. Presenters: Georgie Rack & Owen Bryant Guests: Alexander Natz, Secretary General at EUCOPE - https://www.eucope.org/ Leon van Wouwe, Clinical Innovation Director at VOLV Global https://www.volv.global/ Wing-yun Cheung, General Manager at Terrapinn & organiser of WODC EU - https://www.terrapinn.com/conference/world-orphan-drug-congress/index.stm Chloe Sheppard, Consultant at P4A Joanna Fernandes, Senior Consultant at P4A
Winds of change are howling in Germany, with the draft healthcare bill now approved to stabilise SHI fund finances. What will manufacturers, with innovative orphan drugs and cell and gene therapies, launch strategies be? With the latest decision from Janssen to avoid the German market altogether for x2 Rare Oncology innovative drugs, will this be a trend we are likely to see continue? Join Stefan Walzer & Fisentzos Stylianou discuss the new bill, in regards to the biggest changes that impact orphan drug (OD) manufacturers. Will OD manufacturers still see Germany as the first go to market within Europe and what does this means for rare disease patients? Will there be delays to new treatments or will manufacturers decide not to launch in Germany at all to protect the price of their new drug? We will be discussing this and so much more! If you are a drug manufacturer planning your launch strategy, this podcast is for you! Presenters: Georgie Rack & Owen Bryant Guests Stefan Walzer, CEO President & Founder of MArS Market Access & Pricing Strategy GmbH Fisentzos Stylianou, senior analyst and P4A's German country expert Dr Stefan Walzer, CEO President & Founder at MArS Market Access &Pricing Strategy GmbH https://marketaccess-pricingstrategy.de/en/ Bio & Fun Facts 1) Economist, PhD in health economics, diploma in clinical trials 2) Experience in MA, reimbursement, HE and pricing since 2004 in consultancy and industry 3) Founder and CEO of MArS - THE D-A-CH market access consultancy. Linked to that also co-founder of SMS2DACH including the full spectrum for D-A-CH support (distribution, management, launch, etc.): www.sms2dach.com 4) Founder of P&N (pricing-and-negotiations.ca) with a focus on negotiations across the world including being the co-founder of www.thenegotiationlab.com 5) Member of a European network Tesseract (https://www.tesseracteurope.com/) which can serve companies moving from outside Europe into Europe including not only reimbursement services but also logistics, customs, etc. 6) Teaching at various German universities 7) Love spending time with my family, being a soccer coach of under 14 years-old and being a supporter of Borussia Dortmund Fisentzos Stylianou, Senior Analyst & German Country Expert Fisentzos role at Partners4Access includes conducting primary and secondary research to support the development of market access and reimbursement strategies for clients in the pharmaceutical and biotechnology industries. With a passion for innovative treatments, he closely follows the cell and gene therapy field as it expands to treat more patients with rare diseases. Prior to joining Partners4Access, Fisentzos worked as a Research Associate at Imperial College London, where he also earned his Ph.D. in Structural Biology in 2020. During this time, he conducted research as part of a multidisciplinary team to advance his understanding of the structure and function of biofilm-forming proteins, paving the way for the design of novel antimicrobial therapeutics. Fisentzos also holds an M.Sc. in Biomedical and Molecular Sciences Research and a B.Sc. in Biomedical Science, both from King's College London.
P4A's 2 part -Patient Empowerment podcast series has been released. Our incredible panel of experts Laurence Woollard, Neil Bertelsen & Sophie Schmitz are back with us to carry on the discussion in part 2 on true patient empowerment and really looking at the WHY's! Why should drug manufacturers involve & listen to and involve the patients. What are the implications, if any, for drug manufacturers who do not include the patient voice. How can we bring all stakeholders together to work completely new approaches to medicine approval and patient access. Lastly, we will look at initiatives or services our panel are offering to try to bridge the gaps and barriers for sustainable patient access. P4A's''Let's talk rare'' monthly podcasts are available wherever you listen to your podcasts. If you are a drug manufacturer and you haven't yet listened, this needs to be at the top of your to do list! If you missed out on part 1 - listen here: https://spotifyanchor-web.app.link/e/hOBI3UqkPtb Hosts: Georgie Rack (G-Rack) & Owen Bryant (OB1) Produced by: Operations Team Links: P4A's PCAC: https://partners4access.com/services/pc-council/ Part One: Patient Empowerment: https://spotifyanchor-web.app.link/e/hOBI3UqkPtb ABPI article in recognition of Rare Disease Day 2022 - “Moving beyond box-ticking and lip-service - why patient involvement matters in a new era of ATMPs for rare diseases” James Lind Alliance Priority Setting Partnership - “Setting priorities for bleeding disorders - Final report” (2018) “More than a Top 10: How James Lind Alliance Priority Setting Partnerships transform research, people and organisations” (2019)
This month we have a special 2-part series focused on Patient Empowerment, with special guests Laurence Woollard, On the Pulse, Neil Bertelsen, Independent Consultant & Sophie Schmitz, Managing Partner at P4A. This podcast is a MUST to listen too if you are a company looking to successfully develop and commercialize an orphan drug or ATMP The first part will focus on how do we ensure there is genuine patient involvement at all stages of drug development? What are the challenges and barriers for patients living with a rare disease vs drug developers within the rare/ultra-rare sphere? The second part will solely focus on the WHY! Why should drug manufacturers, payors, regulators and HTA bodies involve and listen to the patients? What do they bring to the table? We will also dive into the implications of not including the patient voice and use examples of companies that have successfully managed to do this and the benefits of doing so. Laurence Woollard, Owner On The Pulse Laurence Woollard is founder and director of On The Pulse – an independent, strategic consultancy providing specialist insight to global healthcare providers and multi-agencies on the development and rollout of patient activation campaigns in haemophilia and rare disease. Laurence has extensive patient advocacy experience, having advised on and implemented a broad scope of community awareness, research and educational initiatives for commercial partners and third-sector organisations. Neil Bertelsen, Independent Consultant Neil Bertelsen is an independent consultant and patient advocate with over 25 years of experience bringing the patient voice to health care decision makers and communicating the science of health care to patients in a way that truly informs their own personal health choices. Neil is passionate about bringing the patient experience and perspectives to decision-makers including industry and health technology assessment (HTA) bodies. Neil is the past chair of HTAi (the global scientific society of HTA) Patient and Citizen Involvement Interest Group. This is an international multi-stakeholder group whose remit is to work alongside HTA organizations and patient organizations to bring patient involvement processes and patient insights and experiences into access decision making processes. Sophie Schmitz, Managing Partner P4A Sophie is managing partner at Partners4Access(P4A),an award winning global consultancy focused on access for orphan drugs & ATMPS. P4A support the biotechnology & pharma industry along their launch journey to help secure successful price, reimbursement and access for orphan drugs & ATMPs. The company has solid partnerships with clients supporting their strategy & operations to effectively launch success.
This month we have put together a slightly different episode with a twist. Georgie & Owen will take you behind the scenes at P4A and discuss 'What makes P4A an award-winning global market access consultancy?' Why we do what we do every day, and what it means to each and every member of staff. Pride, Passion & Partnership are the core values at P4A, and we take a closer look into each one. Later in the show we have a very special announcement from our Managing Partner, Sophie Schmitz. Host: Georgie Rack, Communication Executive & Owen Bryant, Creative Director Produced By: Operations Awards P4A have won in 2022 (so far!) - https://partners4access.com/about/awards/ 1. BOBI Awards 2022 - Analyst Team of the Year Link: https://www.bhbia.org.uk/bobi-awards/award-winners/bobi-2022 2. Benelux Enterprise Awards 2022- Best Orphan Drug & Gene Therapy Experts Link: https://www.eubusinessnews.com/awards/benelux-business-awards/#ourwinners 3. International Life Science Awards 2022 - Best Cell & Gene Therapy Global Market Access Consultancy Link: https://www.ghp-news.com/awards/international-life-sciences-awards/ 4. Healthcare & Pharmaceutical Awards 2022 - Leading Experts in Orphan Drug & Gene Therapy Access Link: https://www.ghp-news.com/awards/healthcare-pharmaceuticals-awards/
In this episode P4A's Richard Wang and Adama Anozie discuss Hospital Exemption (HE) which is an emerging access pathway for Advanced Therapy Medicinal Products (ATMPs). Main topics of discussion include the benefits and potential downsides associated with this pathway, the EU regulations involving HE and recent events in Italy, Spain and France, as well as the implications of HE on the traditional pharma model, the need for collaboration between big pharma and hospitals/institutions to develop HE therapies and much more! Presenter: Richard Wang Contributor: Adama Anozie Producer: Operations Team
In this episode P4A's Senior Client Relationship Director, Bruce Chin discusses his experiences from the in person World Orphan Drug Congress USA 2021. Topics of discussion included travel and safety precautions due to COVID, Bruce's favourite sessions, key learnings from the sessions, and much more! Presenter: Georgie Rack Contributor: Bruce Chin Producer: Operations Team
In this episode, the P4A team take a deep dive into the Brazilian pharmaceutical market and discuss its potential for access to orphan drugs, cell and gene therapies. The overall Latin American pharma market is forecast to grow by 9% per year through to year 2028. However, major markets in this region such as Brazil have some major barriers to access. Listen in to learn more. Presenter and Contributor: Ciaran Cassidy Producer: Aparna Krishnan
Its almost six months since President Joe Biden came to office but the role of the head of the country's key drug regulator, the US Food and Drug Administration (USFDA) is yet to be filled. In this episode, the P4A discusses the absence of a USFDA commissioner and its impact. Also, we understand the significance of recent remarks of the Center for Biologics Evaluation and Research (CBER) director Peter Marks on the need for consistency in the manufacture of cell and gene therapies. Presenter and Contributor: Max Rex Producer: Aparna Krishnan
In this month's episode, the P4A team take a deep dive into the impact of Brexit on the UK's market access landscape. Four months after leaving the European Union, the UK's attractiveness as a key destination for commercialisation of new drugs is being tested. In order to improve its credentials, the UK is exploring a slew of measures that could potentially spark a reform. But will that happen? P4A's Joanna Fernandes and Jayne Watson consider two distinct initiatives - MHRA's (Medicines Healthcare Regulatory Agency's) new I-LAP (Innovative Licensing and Access Pathway) scheme and England's HTA body NICE's (National Institute for Health and Care Excellence's) method review. Presenter and Contributor: Joanna Fernandes Other contributors: Jayne Watson Producer: Aparna Krishnan
In this episode, the P4A team discussed the impact of cost-containment measures in Germany, the European Commission's recent move to revise legislation on orphan medicinal products and potential legislative reforms in the US under the new Biden administration. Presenter: Jens Leutloff Contributors: Chloe Sheppard, Max Rex Producer: Aparna Krishnan
Most of this week's episode is focused on P4A memes and memories, but we're also sharing our initial reactions to Clubhouse and Payton's absolutely foul dream. Also, Payton invents the half'on and the whole'on, and we create 1996's new generation, Generation No. Stay tuned 'til the very end to hear Brint's latest edition of BABFER (ABFE spoilers after the outro!) Follow us on Twitter at twitter.com/retweetthispod to see what we're talking about, and send us your favorite tweets and viral moments of joy with #mcdicklez! Follow Payton: twitter.com/desertplantdan Follow Emily: twitter.com/phiIsthiccbooty Patreon: patreon.com/retweetthis --- Support this podcast: https://anchor.fm/retweetthis/support
In this episode, the P4A team review all the key events of the year 2020 in the orphan drug, cell and gene therapy world. The emergence of COVID-19 pandemic has caused disruption but also opportunities for the biotech industry. From change in regulations, new stakeholder collaborations to impact of Brexit and US drug pricing reforms, a full round up of 2020. So do listen in! Presenter and Contributors: Sophie Schmitz and Akshay Kumar Producer: Aparna Krishnan
Show Flow1- intro 2- Last Week show - Kiss the ground3- Big story of the day - 4- Meetings and events industry -4- Update on One for the Ages- 5- Update on P4A podcast - market research option-6- Show and tell (one or two things-- something you are watching, reading listening to, doing ) Notes: (number is associated with segment- mm= Mike McAllen/GG= Geraldine Gatehouse)2) MM Kiss the ground - The message is too simple, The good (soil health) versus (chemical) bad farmer is not the best way to get the chemical dependent farms onboard.No mention of how these shifting needs public investment for the technical resources to adapt and shift. COWS --After looking at all of the available evidence on holistic grazing, and claims made by the likes of the movie, 'grass-fed livestock are not a climate solution'. Grazing livestock are net contributors to the climate problem, as are all livestock. Rising animal production and consumption, whatever the farming system and animal type, is causing damaging greenhouse gas release and contributing to changes in land use. Ultimately, if high consuming individuals and countries want to do something positive for the climate, maintaining their current consumption levels but simply switching to grass-fed beef is not a solution. Eating less meat, of all types, is.Good news- Governor Newsom announced an executive order to elevate the importance of stewardship of our lands to secure our future. It is great Governor’s focus on climate solutions for agriculture and our natural resources at large. We cannot address the state’s profound wildfire risks without addressing the conservation and management of our forests, grasslands, and farmlands. Nor can we address our pandemic-induced recession without addressing the resilience of California’s food and farming systems.3. GG Big story - for me, Goldman Sachs: A democratic sweep would mean faster economic recovery. Contrary to what the president is saying, GS says that polls suggest a blue wave in which Democrats take control of Washington, and they in turn would upgrade their forecasts. Taxes may go up but Biden is promising a bonanza of government spending that, couple with extremely low-interest rates, would likely speed up the economy.I just watched Biden in his Florida Town Hall )- the WH declined the invitation - and it was refreshing to hear whole sentences, sensible responses, and a caring approach. It gave me a bit of heart. Unfortunately, I saw headlines about it being a bit of a setup, so need to look more into that.GG - Awful quote of the day: Senator Mike Lee - Democracy isn’t the objective. Liberty, peace and prosperity are. We want the human condition to flourish. Rank democracy can thwart that.3 MM In a few days, more people in Trump’s orbit tested positive for coronavirus than in all of Taiwanhttps://www.msn.com/en-us/news/world/in-a-few-days-more-people-in-trump-s-orbit-tested-positive-for-coronavirus-than-in-all-of-taiwan/ar-BB19LxxU?utm_source=nextdraft&utm_medium=emailMore than a dozen White House officials have recently tested positive for the novel coronavirus, including some who are among the at least nine guests and two journalists who tested positive after they attended Amy Coney Barrett’s Sept. 26 Supreme Court nomination event in the Rose Garden. Trump announced his positive test early Friday, and was admitted to Walter Reed National Military Medical Center later that day. He returned Monday to the White House, where he removed his mask, despite doctors saying he was still contagious. Meanwhile, Taiwan — the self-ruled island home to 23 million people — reported just eight new cases in the past week.4. GG I’m waiting to work on the transcripts for the four episodes I’ve done and have two more in the works which I’m scheduled to finish up the week after next. The two subjects are on loneliness and brain health.5) MM P4A - Market Research Option- Topics and revenue (with Geraldine) -----Moving the first client to dynamic ad and promos. Moving MeetingsPodcast.com and Donald Don't Grab that pussy to test. Currently using Libsyn which the meetings podcast has been with since 2006. ---Opened ThePodcastguys.com to help mostly local podcasters. 6. GG Talking to Strangers in a Pandemic Meet Cart maven Emily Hope Dobkin, founder of a company called Betterish, brings people together by having them share their stories in online sessions. Emily Hope Dobkin is the creator of the “Meet Cart,” an actual cart that Dobkin once wheeled around Denver as a prop at the pop-up events and hands-on workshops that she presented at festivals and other events and venues. A one-time arts educator, last year Dobkin founded a company called Betterish, which brings diverse groups of strangers together to share their stories. “Everyone you meet,” she says, “has something valuable to teach us.”The pandemic put a halt to Dobkin’s mobile cart, but not to her efforts to connect strangers. “Amidst the pandemic, though we are finding new ways to connect with friends and family,” Dobkin said, “we’re not able to connect to new, fresh faces.” That matters, because research shows that our interactions with strangers create what sociologists call “fleeting intimacy,” and that people often are more open about their inner selves with strangers than they are with their friends and families.https://www.pcma.org/betterish-share-stories-covid-19-networking/?utm_source=pardot&utm_medium=newsletter&utm_campaign=careercenter&utm_term=organic6. GG I plan on getting chicks by the end of this month. Next week is a busy one and I need to get all the stuff sorted for the little tikes. I’ve had hens before but not chicks since I was a little tike so I am excited about that. They’ll need to live in my spare bedroom as they need warmth. I’ve signed up for a how to care for your chicks webinar. Bit concerned about the dogs’ reaction but I think they’ll get used to them.6. GG I have a prolific vine that is giving me loads of passionfruit and never was quite sure what to do with them, until now. They are a bit offputting to look at - a bit testicle-like, but they are scrumptious if you squeeze the juice from the seeds and use that to make vodka cocktails. And they are delicious with plain yogurt and honey; the fruit is a tad tart so the honey just takes that edge off. Do you still have your bees, by the way, Mike? (yes he does) 6. MM Good news-https://www.cnn.com/2020/10/05/weather/us-lightning-strike-deaths-trnd/index.html?utm_source=nextdraft&utm_medium=emailI know here in California the lightening complex has started some horrible fires- My family and I rode it out camping in my rooftop tent. In a year of increasingly bleak headlines, here's one uplifting piece of news: The US is on track to experience the fewest recorded deaths from lightning strikes in a single year.
Show Flow 1- intro 2- Last Week show 3- big story of the day RGB- 4- Update on One for the Ages 5 Update on P4A podcast 6- Show and tell Ruth Bader Ginsburg https://en.wikipedia.org/wiki/Ruth_Bader_Ginsburg https://www.youtube.com/watch?time_continue=64&v=qze13ssb92w&feature=emb_logo Social Dilemma- https://www.netflix.com/title/81254224 Everybody who owns a Cell phone should watch this. Quote- Users are terms drug dealers and social media platforms use. Jeran Lanier - http://www.jaronlanier.com/ Sam Harris Tristan Harris Center for humane technology https://www.humanetech.com/ Octopus is my Teacher- Netflix https://www.netflix.com/title/81045007 One mans love affair with a Octopus What I am listening to -- Jennifer Briney - Post office… Congressional Dish- Post office https://congressionaldish.com/cd220-postal-service-sabotage/ The mail has been slow this summer, no doubt about it, but did the Trump administration slow the mail down on purpose in order to interfere with mail-in voting? In this episode, listen to highlights of recent emergency Congressional hearings in order to learn what’s really going on at USPS. The sabotage is real, but the situation is different from what you probably think. Special guest: Alexis Claypool Glaser Lebron James and Patrick Mahomes - More than a vote- voter suppression-https://www.morethanavote.org/ More Than A Vote is a coalition of Black athletes and artists working together to educate, energize, and protect our community. That starts with raising our hands and registering to vote, and working to combat lies, myths, misinformation and voter suppression that stands in the way of our ability to vote. Stand with us and register to vote now — so we step into our power at the polls on November 3 Talking to Strangers in a Pandemic https://www.pcma.org/betterish-share-stories-covid-19-networking/?utm_source=pardot&utm_medium=newsletter&utm_campaign=careercenter&utm_term=organic Power through the people - Sekou Andrews, grammy-nominated poet and creator of Poetic Voice speaking category - poetry & inspirational speaking - sort of a Hamilton meets Ted. http://sekouandrews.com/ Greg DeShields, Executive Director of PHLDiversity, a division of the Philadelphia CVB - also speaking at IMEX - part of panel on Diversity, Equity and Inclusion https://globalphiladelphia.org/people/greg-deshields Had blog published by IMEX on David Allison of Valuegraphics = a new way of looking at data (imex website) https://valuegraphics.com/ https://www.imexexhibitions.com/insight/blog/data-beyond-the-numbers Stacy Abrams All in: the fight for democracy. Voting is hard in the US. American elections ranked worst among Western democracies. AP News, January 2019. Variety of reasons, insufficiently trained poll workers, confusion over ID requirements, gerrymandering, the role of money. Amazon Prime-- https://www.amazon.com/All-Fight-Democracy-Stacey-Abrams/dp/B08FRV55VB/ref=sr_1_1?dchild=1&keywords=All+in%3A+the+fight+for+democracy&qid=1600711604&s=instant-video&sr=1-1
The team discuss the NORD summit particularly FDA commissioner Scott Gottleib’s presentation, panel discussion on cell and gene therapy pricing as well as P4A’s lunch and learn on cell and gene therapy access – learnings from the EU. Also in this episode, Novartis’ Kymriah innovative payment agreement in Italy, the changing evaluation trends for gene therapies among HTA bodies and Alliance for Regenerative Medicines’ Q3 report. Presenter: Jack Rawson Contributor: Sophie Schmitz Producer: Aparna Krishnan
In this episode, P4A speaks to a special guest - Alliance of Regenerative Medicine's chief executive officer Janet Lambert on the ARM's key initiatives such as the Foundation of Cell and Gene Therapy medicines as well as the 2019 report on ATMPs (Advanced Therapy Medicinal Products). Presenter: Aparna Krishnan Contributor: Janet Lambert, CEO of Alliance of Regenerative Medicine Producer: Aparna Krishnan
This week, the P4A team discuss the coverage of Novartis' Zolgensma in the US in particular how US health insurers have received the gene therapy. Also on the agenda was the impact of Zolgensma's launch on rival Biogen's Spinraza and the potential for dominance of the gene therapy in the spinal muscular atrophy landscape. Presenter: Aparna Krishnan Contributor: Max Rex Producer: Aparna Krishnan
On our anniversary episode, the P4A team discuss the USFDA approval of Novartis' Zolgensma, a one time gene therapy for paediatric spinal muscular atrophy patients and a look back at the last 12 months of our podcasting journey. Presenter: Joanna Fernandes Contributor: Christina Poschen, Aparna Krishnan Producer: Aparna Krishnan
This week, the P4A team discuss a new experimental therapy - Phage therapy or genetically engineered phages in order to treat bacterial infections and the acquisition of Theracon by Big Pharma firm Pfizer for upto $810 million. Presenter: Aparna Krishnan Contributor: Ciaran Cassidy Producer: Aparna Krishnan
As part of the continuing World Orphan Drug Congress (WODC) special, this episode discusses the cGMP facilities and biosafety solutions from Germfree’s Carol Houts, P4A’s Sophie Schmitz looks back at the 2019 conference and Terrapinn’s Andre Singer talks about what to expect from WODC 2020. Presenter and Producer: Aparna Krishnan Contributors: Carol Houts, Director of Regulatory and Quality, Germfree; Sophie Schmitz, Managing Partner, Partners4Access and Andre Singer, General Manager for World Orphan Drug Congress USA, Terrapinn
This week, the P4A team are podcasting from the World Orphan Drug Congress in Washington D.C. We speak to André Choulika, Chairman and CEO of Cellectis on the challenges of commercializing a CAR-T cell product and ethical concerns surrounding it, and Anna Bucsics from the Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA) on their work supporting new biotech entrepreneurs. Presenter: Joanna Fernandes Contributors: André Choulika, Chairman and CEO of Cellectis; Anna Bucsics, Project Advisor to MoCA and Sophie Schmitz, Managing Partner, P4A Producer: Aparna Krishnan
This week, the P4A team discuss the spate of mergers and acquisitions involving Big Pharma companies in the gene therapy space. Particularly, we looked at the deals behind Roche's acquisition of Spark Therapeutics and Biogen's buyout of Nightstar. Also, Vertex's continued struggle to get its cystic fibrosis drug Orkambi reimbursed in the UK. Presenter: Joanna Fernandes Contributor and Producer: Aparna Krishnan
On Rare Disease Day, P4A discusses the role of policy-makers in the healthcare system and specifically, the issues surrounding cross-border healthcare as part of its '6P' campaign. This directive is a key cornerstone legislation by EU officials that enables patients to find treatment in healthcare facilities outside their home country. However, there are several challenges associated with it. Presenter: Christina Poschen Contributor: Dr Andrzej Rys, Director - Health Systems and Products Producer: Aparna Krishnan
Throughout February 2019, the P4A team are hosting a series of special edition podcast episodes to mark Rare Disease Day. The initiative is part of a new 6P campaign aimed at promoting awareness about rare disease challenges and its impact on people and society. The 6Ps are Partnership, Policy-maker, Payer, Pharma, Physician and Patient. Our message: 6Ps are essential to successfully serve the rare disease community and achieve access to medicines. This week, we discuss the first P – Partnership. The team reflects on the meaning of partnership in the rare disease context and what it can achieve through examples of different types of collaborations. From patient and clinical experts influencing HTA decisions; key stakeholders coming together for the Hercules Project to a collaboration between US based ICER, Canada's CADTH and UK's NICE. Presenter: Aparna Krishnan Contributors: Sophie Schmitz, Christina Poschen, Max Rex, Joanna Fernandes, Nader Murad and Jack Rawson
This week we are looking at the USFDA’s proposed plans to address the expected rise in cell and gene therapy product applications and a significant development in a new controversial procedure called gene drive. Also, P4A is starting a new campaign that will run throughout February to mark Rare Disease Day. The '6P' campaign is aimed at creating awareness on the impact of rare diseases on key stakeholders and the need for partnership to achieve successful treatment access for patients. The 6Ps are Partnership, Patient, Policy-maker, Physician, Pharma and Payer. P4A will roll out a series of podcast episodes featuring thought leaders representing these stakeholders. So make sure you listen in! Presenter: Joanna Fernandes Contributors: Nader Murad and Sophie Schmitz Producer: Aparna Krishnan
This week, the P4A team discusses the Louisiana Medicaid program implementing the 'Netflix' subscription model to pay for hepatitis C drugs and the potential Brexit options facing the UK government. Presenter: Joanna Fernandes Contributor: Max Rex Producer: Aparna Krishnan
Happy New Year to Weekly Roundup listeners! 2019 is shaping up to be an exciting year for the healthcare and biotechnology industry. We are only a couple of weeks in and already news developments are buzzing on the regulatory and corporate front. So for this week's episode, we start by discussing the recent wave of mergers and acquisition deals announced by Big Pharma namely, Eli Lilly and Loxo; BMS and Celgene as well as GSK and Tesaro. Also, the P4A team look at the implications of the current US government shutdown on the FDA and the agency's initiative on assessments for innovative drugs. Presenter : Max Rex Contributor : Joanna Fernandes Producer: Aparna Krishnan
In the last episode of 2018, the P4A team look back at the events of the year and particularly on how their predictions on key trends in the rare disease space have fared. Presenter: Aparna Krishnan Contributors: Mergers and acquisitions - Sophie Schmitz Rare oncology drug approvals - Joanna Fernandes Future of new technologies like gene therapies - Christina Poschen Increasing prominence of societal burden data - Nader Murad Emphasis on planning Real World Evidence - Aparna Krishnan U.S drug prices - Max Rex The Weekly RoundUp team will be back in the new year.
Hank and Katherine have a short episode this week, though there are lots of draft tweets saved and not released during the P4A. Also, yes, it is too much to ask for there to be a boyband composed of 50 year olds. And let's talk a bit about the TUMBLR NEWS!!!
The P4A team discuss the latest update on Brexit and its implication on life science companies; Novartis' CAR-T therapy commercialization efforts and the Hercules Project, a unique initiative supporting new drug reimbursements in Duchenne Muscular Dystrophy. Presenter: Aparna Krishnan Contributors: Joanna Fernandes and Sophie Schmitz
In the second part of our World Orphan Drug Congress special, P4A's Sophie Schmitz speaks to Diane Kleinermans, adviser to the Belgian Federal Government on the origins and future of the Beneluxa initiative. Presenter: Aparna Krishnan Contributors: Sophie Schmitz, Managing Partner, P4A and Diane Kleinermans, Adviser to the Ministry of Health and Social Affairs, Belgium
In the first of a two-part special, the P4A team are at the World Orphan Drug Congress in Barcelona discussing access to new treatments with a Porphyria patient; hear from a company offering a unique service to clinical trial patients; a special interview with Ségolène Aymé on rare disease challenges and a chat with organisers of the congress. Presenter: Aparna Krishnan Contributors: Sophie Schmitz, Managing Partner, P4A; Dr Jasmin Burman-Aksözen, Vice President of International Porphyria Patient Network; Helen Springford, Vice President, Illingworth Research Group; Prof Ségolène Aymé, Founder of Orphanet; Andrew Mears, Business Development Manager at Terrapinn
This week, the P4A team analyse the new regulations surrounding health technology assessments in Europe and US-based CAR-T start-up Allogene Therapeutic's record-breaking initial public offering. Presenter: Max Rex Contributor: Christina Poschen, Consultant, P4A
The P4A team analyze Novartis' deal with Celluar Biomedicine Group to supply the CAR-T therapy Kymriah and the successes and failures of the reimbursement of Vertex's cystic fibrosis drug, Orkambi. Presenter: Max Rex Contributor: Nader Murad, Senior Analyst
This week, P4A's podcast will cover Luxturna's CHMP recommendation, Novartis' restructuring plans and Alexion's acquisition of Syntimmune. Presenter: Max Rex Contributor: Aparna Krishnan
This week I talk about my love for the P4A series to piggyback off of my recent feature The Future of the Persona 4 Arena Series, as well as a recap of the Tekken World Tour Final. Topics on this week's show include: Tekken World Tour Final recap Thoughts on the Persona 4 Arena Series
Back from a summer break! The P4A team discuss the reasons behind NICE's rejection of Novartis' CAR-T therapy Kymriah, Denmark and Norway's joint drug purchasing agreement and US patient groups pushing back against ICER's influence in drug reimbursement. Presenter: Max Rex Contributor: Aparna Krishnan
In this episode, P4A discusses the UK government’s publication of four key documents guiding the life science industry on how to operate during the Brexit transition period; Spark Therapeutics' clinical data for its gene therapy treating heamophila A patients and finally, the Irish government plans to reform the country’s healthcare system. Presenter: Joanna Fernandes Contributor: Aparna Krishnan
The EU's Commissioner for Competition Margrethe Vestager, recently said that price differences in the pharma market among different member states could be “justified”. This week, P4A delves deeper into the mechanics of drug pricing in Europe including discussing the impact of parallel trade and comparing it to U.S. pricing. Presenter: Max Rex Contributor: Stuart Tutt
The U.S. FDA's new guidance on gene therapy was recently announced by FDA Commissioner Dr. Scott Gottlieb, the P4A team discuss key implications of these guidelines along with an update on UK's Brexit Whitepaper and new measures by the French government to improve patient access to innovative drugs. Presenter: Joanna Fernandes Contributors: Christina Poschen & Aparna Krishnan
This week, the P4A team discuss the CHMP approval of two CAR-T Therapies; Scotland's new rules for ultra-orphan drugs and the reaction to the announcement of National Coverage Analysis for CAR-T drugs in the U.S. Presenter: Max Rex Contributors: Sophie Schmitz, Managing Partner & Alison Kneen, Vice President, International Operations
This week, the P4A team delve into the pharma industry's proposal to the EU on the role of national HTA bodies post harmonization of clinical assessments for innovative drug technologies; the European Medicines Agency's new portal for orphan drug designation applications and Ireland's entry into the Beneluxa Initiative. Host: Joanna Fernandes Contributor: Aparna Krishnan
The P4A team give a summary of the gene therapy FDA news this week and also discuss President Trump's drug pricing plans for Medicare and UK cost watchdog NICE's rejection of Crysvita. Presenter: Max Rex Contributors: Aparna Krishnan, Joanna Fernandes
This week the P4A team discuss key advancements in oncology treatments - a genetic test indicating whether chemotherapy is beneficial in a particular breast cancer patient group and successful results of an immunotherapy using T cells in an advanced breast cancer patient. In addition, news involving a potential new sickle cell therapy under development. Presenter: Max Rex Contributors: Alison Kneen and Aparna Krishnan
In its very first podcast of Rare Disease, Cell & Gene Therapy Weekly RoundUp, P4A discusses the US FDA's accelerated regulatory process for gene therapy; President's Trump's proposed drug pricing plan; the European Commission's proposal to amend SPC; the NHS England budget ringfencing; Irish government's attempt to trim the HSE and the new GDPR laws. Max Rex hosts with contributions from Aparna Krishnan, Corporate Affairs Lead and Alison Kneen, Vice President, International Operations.
40- Quina es la teva fruita preferida?Bon dia, noies i nois, avui és Dimecres 16 de maig del 2018 i parlarem de Fruita i esport.Anuncis del dia:Que et sembla si la teva veu surt a la radio de l’escola?? Xulo oi??? Doncs es molt fàcil li dius a la mama o al papa que m’enviïn un àudio comentant … Quina es la teva fruita preferida a i perquè et dona energia… al 650 25 32 24.Hola soc el Gerard de P4A i m’agrada la poma i em dona energia per fer-te companyia.Recorda:El dissabte 26 de maig Tindrà lloc a les instal·lacions del pati de l’Escola Pràctiques durant tot el matí des de les 9:30h del matí fins les 12:30h el torneig 3x3. Apuntat a la butlleta del teu mail.Avui al menjador tenimDe primer: Amanida de llenties (llenties, enciam , ceba i olives)De segon: Filet de llenguado enfarinat amb salsa de tomàquetI per a postres: FruitaBon profit!Avui fan anys:Avui NO fa anys ningú així que us desitgem un Feliz Feliz NO CumpleañosI tu si escoltes i no t’has apuntat apuntat al formulari a les notes del programa.https://goo.gl/forms/scJTWKesOZIAvbF83 (enllaç al formulari). Apuntat. Aquest programa Podcast el pots escoltar com i quant vulguis a ivoox Spreaker itunes Podcast i Youtube ...Si vols estar informat subscriu-te i dona-li al like… aYoutubehttps://www.youtube.com/channel/UCfbX...ivooxhttp://www.ivoox.com/s_p2_486641_1.htmlSpreakerhttps://www.spreaker.com/show/2804548itunes Podcast.https://itunes.apple.com/es/podcast/b...Fins demà!#Podcast #PodcastComunidad #PodcastComunicación #AMPA #PODCASTEALO
40- Quina es la teva fruita preferida?Bon dia, noies i nois, avui és Dimecres 16 de maig del 2018 i parlarem de Fruita i esport.Anuncis del dia:Que et sembla si la teva veu surt a la radio de l’escola?? Xulo oi??? Doncs es molt fàcil li dius a la mama o al papa que m’enviïn un àudio comentant … Quina es la teva fruita preferida a i perquè et dona energia… al 650 25 32 24.Hola soc el Gerard de P4A i m’agrada la poma i em dona energia per fer-te companyia.Recorda:El dissabte 26 de maig Tindrà lloc a les instal·lacions del pati de l’Escola Pràctiques durant tot el matí des de les 9:30h del matí fins les 12:30h el torneig 3x3. Apuntat a la butlleta del teu mail.Avui al menjador tenimDe primer: Amanida de llenties (llenties, enciam , ceba i olives)De segon: Filet de llenguado enfarinat amb salsa de tomàquetI per a postres: FruitaBon profit!Avui fan anys:Avui NO fa anys ningú així que us desitgem un Feliz Feliz NO CumpleañosI tu si escoltes i no t’has apuntat apuntat al formulari a les notes del programa.https://goo.gl/forms/scJTWKesOZIAvbF83 (enllaç al formulari). Apuntat. Aquest programa Podcast el pots escoltar com i quant vulguis a ivoox Spreaker itunes Podcast i Youtube ...Si vols estar informat subscriu-te i dona-li al like… aYoutubehttps://www.youtube.com/channel/UCfbX...ivooxhttp://www.ivoox.com/s_p2_486641_1.htmlSpreakerhttps://www.spreaker.com/show/2804548itunes Podcast.https://itunes.apple.com/es/podcast/b...Fins demà!#Podcast #PodcastComunidad #PodcastComunicación #AMPA #PODCASTEALO
21- Tornem a l’EscolaBon dia, noies i nois, Avui és Dimarts 3 d'abril del 2018 i s'han acabat les vacances.... o nooooo però, tornem a l'escola.... Bieeeennnn!Anuncis del dia:Si veus a la Carla de 4t, la Carla Plana, felicita-la! Ha obtingut el primer premi en les 3 pistes de França, un esdeveniment internacional de patinatge de velocitat. Felicitats campiona!Recorda:Que el diumenge tenim el Cros, si t'has despistat i no has entregat la butlleta... Vola i dóna-li a la Joana. Demà t'informarem dels horaris... Mentrestant vés escalfant motors...Avui al menjador tenimDe primer: Macarrons amb sofregit de tomàquet gratinats al fornDe segon: Hamburguesa mixta a la planxa amb enciam, pastanaga i olivesI per a postres: FruitaBon profit!Avui fan anys:Avui no fa anys ningú, però la setmana passada van fer aniversari la Judit Uribe de 6è-A,Elian de P4A, i la María de 5è A. Felicitats!!!!Esperem que ho hàgiu passat molt bé... com que avui ja no és el vostre aniversari, ús desitgem un... Feliz No cumpleños.Recorda apuntar-te al formulari perquè et felicitem a les notes del programa.https://goo.gl/forms/scJTWKesOZIAvbF83 (enllaç al formulari). Apuntat.Aquest programa Podcast el pots escoltar com i quant vulguis a ivoox Spreaker itunes Podcast i Youtube ...Si vols estar informat subscriu-te i dona-li al like… aYoutubehttps://www.youtube.com/channel/UCfbX...ivooxhttp://www.ivoox.com/s_p2_486641_1.htmlSpreakerhttps://www.spreaker.com/show/2804548itunes Podcast.https://itunes.apple.com/es/podcast/b...Fins demà!#Podcast #PodcastComunidad #Comunicación #Escola #AMPA
21- Tornem a l’EscolaBon dia, noies i nois, Avui és Dimarts 3 d'abril del 2018 i s'han acabat les vacances.... o nooooo però, tornem a l'escola.... Bieeeennnn!Anuncis del dia:Si veus a la Carla de 4t, la Carla Plana, felicita-la! Ha obtingut el primer premi en les 3 pistes de França, un esdeveniment internacional de patinatge de velocitat. Felicitats campiona!Recorda:Que el diumenge tenim el Cros, si t'has despistat i no has entregat la butlleta... Vola i dóna-li a la Joana. Demà t'informarem dels horaris... Mentrestant vés escalfant motors...Avui al menjador tenimDe primer: Macarrons amb sofregit de tomàquet gratinats al fornDe segon: Hamburguesa mixta a la planxa amb enciam, pastanaga i olivesI per a postres: FruitaBon profit!Avui fan anys:Avui no fa anys ningú, però la setmana passada van fer aniversari la Judit Uribe de 6è-A,Elian de P4A, i la María de 5è A. Felicitats!!!!Esperem que ho hàgiu passat molt bé... com que avui ja no és el vostre aniversari, ús desitgem un... Feliz No cumpleños.Recorda apuntar-te al formulari perquè et felicitem a les notes del programa.https://goo.gl/forms/scJTWKesOZIAvbF83 (enllaç al formulari). Apuntat.Aquest programa Podcast el pots escoltar com i quant vulguis a ivoox Spreaker itunes Podcast i Youtube ...Si vols estar informat subscriu-te i dona-li al like… aYoutubehttps://www.youtube.com/channel/UCfbX...ivooxhttp://www.ivoox.com/s_p2_486641_1.htmlSpreakerhttps://www.spreaker.com/show/2804548itunes Podcast.https://itunes.apple.com/es/podcast/b...Fins demà!#Podcast #PodcastComunidad #Comunicación #Escola #AMPA
14- Volem que nevi!Bon dia, nois i noies, Avui és 27 de febrer del 2018I al meteocat diuen...Anuncis del dia:La Neu, no es poca cosa… si neva segur que voldreu fer un ninot de neu ¿oi que sí?Recorda:Pots aprendre a fer un ninot de neu amb aquesta pel·lícula:The Snowman: https://youtu.be/5A3THighARUI amb aquesta una mica més actual:https://www.filmaffinity.com/es/film926588.htmlAvui al menjador tenim:De primer: Macarrons bolonyesaDe segon: Cuixa de pollastre a l'ast amb amanida d'enciamI per a postres: FruitaBon profit!Avui fan anys:Avui fa anys l’ Ariadna de P4A, la meva neboda i fillola a la vegada, que sàpigues que tastimuuuu. Guapa!I demà fan anys la Joana Fabregat de 1erA i la Xantal de 1erB.Us desitgem que passeu un GRAN dia amb la millor companyia.... Rodolí.Recorda apuntar-te al formulari per que et felicitem a les notes del programa.https://goo.gl/forms/scJTWKesOZIAvbF83 (enllaç al formulari). Apuntat. Aquest programa Podcast el pots escoltar com i quant vulguis a ivoox Spreaker itunes Podcast i Youtube ...Si vols estar informat subscriu-te i dona-li al like… aYoutubehttps://www.youtube.com/channel/UCfbX...ivooxhttp://www.ivoox.com/s_p2_486641_1.htmlSpreakerhttps://www.spreaker.com/show/2804548itunes Podcast.https://itunes.apple.com/es/podcast/b...Fins dijousGràcies#Podcast #PodcastComunidad #Comunicación #Escola #AMPA
14- Volem que nevi!Bon dia, nois i noies, Avui és 27 de febrer del 2018I al meteocat diuen...Anuncis del dia:La Neu, no es poca cosa… si neva segur que voldreu fer un ninot de neu ¿oi que sí?Recorda:Pots aprendre a fer un ninot de neu amb aquesta pel·lícula:The Snowman: https://youtu.be/5A3THighARUI amb aquesta una mica més actual:https://www.filmaffinity.com/es/film926588.htmlAvui al menjador tenim:De primer: Macarrons bolonyesaDe segon: Cuixa de pollastre a l'ast amb amanida d'enciamI per a postres: FruitaBon profit!Avui fan anys:Avui fa anys l’ Ariadna de P4A, la meva neboda i fillola a la vegada, que sàpigues que tastimuuuu. Guapa!I demà fan anys la Joana Fabregat de 1erA i la Xantal de 1erB.Us desitgem que passeu un GRAN dia amb la millor companyia.... Rodolí.Recorda apuntar-te al formulari per que et felicitem a les notes del programa.https://goo.gl/forms/scJTWKesOZIAvbF83 (enllaç al formulari). Apuntat. Aquest programa Podcast el pots escoltar com i quant vulguis a ivoox Spreaker itunes Podcast i Youtube ...Si vols estar informat subscriu-te i dona-li al like… aYoutubehttps://www.youtube.com/channel/UCfbX...ivooxhttp://www.ivoox.com/s_p2_486641_1.htmlSpreakerhttps://www.spreaker.com/show/2804548itunes Podcast.https://itunes.apple.com/es/podcast/b...Fins dijousGràcies#Podcast #PodcastComunidad #Comunicación #Escola #AMPA
Hank Green is one half the YouTube creators The Vlog Brothers, who he co-creates with his brother John Green. Hank is the entrepreneurial brother who has the leadership role on many of their co-ventures and has launched several of his own innovative charitable and education-based projects. But going back to 2006, when Hank and John Green first started to collaborate, YouTube was the dominant platform. And that’s where they first emerged as pioneers in the Influencer Economy. “It was 2007, YouTube had been around culturally and people had known of it for about a year,” Hank said of his origins on the platform. So they just started making videos, creating Brotherhood 2.0, a year during which the Green brothers communicated daily with each other by video instead of by phone, e-mail, or text messages. “A fun, jokey, trying-to-one-up-each-other brother project” is how Hank explained it. One of his vlogs to John, a musical tribute to Harry Potter and the Deathly Hallows, made the front page of YouTube. Many fans attribute their discovery of the Greens’ yearlong experiment to that “Accio Deathly Hallows” song—coming across the video and then binging on the rest of the vlogs. After their successful year of Brotherhood 2.0, the Greens honed their vision and created their new Vlogbrothers YouTube channel with similar content and shared it with a growing community that they called “Nerdfighters.” This online community of Vlogbrothers’ supporters joined forces with Hank and John, and their vision evolved over time. Please leave the podcast a review on iTunes. The iTunes link. It helps new people learn about the podcast and we would greatly appreciate your support. :) Here’s how Hank explained what Nerdfighters are fighting for: “I do like the idea that a goal of humans is to decrease suck and increase awesome. That was a saying from early Vlogbrothers. But those are two different things. It’s so objectively better to decrease suck. You know, people have awful lives. People die of preventable diseases, hunger, wars . . . These are problems we can solve. The only reason we aren’t solving them is because we haven’t applied the right amount of resources, both cognitive and monetary. And that’s messed up. But you can’t go through life just playing defense. You also have to do interesting things. You have to send a rover to Mars and have the World Series. These things are good. They help us lead full lives and allow us to apply ourselves to other goals.” I first knew Hank and John as the creators of VidCon, the largest conference for online video world, bringing together over 20,000 video content creators, the web video online community, and industry executives to an annual conference in Anaheim, California. It’s my favorite conference in the world because it’s the only conference where the community, creators, and companies all hang out under one roof. I have attended VidCon since its inception, when it was just a couple hundred people hanging out at a hotel bar and ballroom in the Century City neighborhood of Los Angeles. Even before VidCon, the Vlogbrothers understood how YouTube-wide collaborations could help to improve lives. Since 2007, their Project for Awesome (P4A) has been an annual call for videos from fellow YouTubers and Nerdfighters that highlight charitable causes in everything from education and health care to food insecurity. In December of each year, thousands of people post videos on the across YouTube, where both influencers and the community promote and raise funds for these charities. Video creators are instructed to tag the videos with P4A in the video descriptions in order to help The Vlogbrothers and others discover each video. Joining forces with the crowdsourcing website Indiegogo, the 2014 and 2015 Project for Awesome managed to raise over a million dollars. By 2013, Crash Course and SciShow had both outlived the start-up money provided by YouTube. This got Hank thinking that it was time to roll out a voluntary subscription service that enabled fans to fund his education programming and the work of other online creators. “It’s tied into this idea that we want to help creators create professionally. We want to do that for ourselves and for other people because it’s a great job.” He and his brother launched the crowdfunding website Subbable, which was enormously helpful to more than 20 artists and creators, as well as the fans who love their work. Patreon, the San Francisco–based crowdsourcing company, acquired the website two years after it went live. Hank said both companies started at about the same time and have obvious similarities. “When Patreon launched, we were like ‘Whaaat?!’ because, of course, we had been working on it for six months. I called [Jack Conte, the founder] because I had known Jack before then and said, ‘Just so you know, I’m about to launch the exact same thing, but we’ve spent so much money on it that we can’t not do it.’” It’s hard to say if Hank and John will also end up saving the planet. After all, this is still the early days of the Nerdfighters’ fight. But just from the vibe at VidCon alone, it already looks like the world sucks a little less. For Hank personally, the conference and his other enterprises have at least become rewarding in ways that he never anticipated. “Running a business is a creative thing, like dealing with people and getting the best work out of them. Understanding their motivations aren’t the same as your motivations. It’s all a bunch of moving parts, a piece of artwork in its own way. The fact that I get to do 20 different things, and that Monday looks nothing like Tuesday, is just really satisfying to me. It’s allowed me to build up a toolkit of both personal skills and, you know, having all of these great people who work with me—it allows for creativity on a level that I never believed I could have access to." Hank and John Green's Vlog Brothers YouTube Channel: https://www.youtube.com/user/vlogbrothers Don't Forget to Be Awesome: http://store.dftba.com/ Hank Green's website: http://www.hankgreen.com/ VidCon: http://vidcon.com/ Project for Awesome: http://www.projectforawesome.com/ Crash Course: https://www.youtube.com/user/crashcourse SciShow: https://www.youtube.com/user/scishow
Happy Monday! Episode 33 of RDGH has arrived, and with Destiny live and kicking and August's NPD results in, there's plenty to talk about as usual. Join host Glenn Gordon, Ben Shillabeer-Hall, Garri Bagdasarov, and Fraser Miller for great video game news and discussions. First, Sony Denmark decided to "troll" Microsoft, but the two entities seem rather friendly! Then, we take a look at how Xbox is doing in Japan, and how the mystifying and now infamous parity clause in ID@Xbox's contracts has chased away another game. Sony has also released a list of all the games it will present at Tokyo Game Show 2014, and Microsoft is planning to buy Majong, the developer behind Minecraft--or at least it was at the time of recording, which was yesterday, the 14th of September. As of today, the purchase has been confirmed. Tune in next week for more on that. Destiny's first reviews haven't met expectations, meanwhile--but those who play the game seem to love it. Is something wrong with reviews, and with reviewers? Speaking of which, Glenn has a beef with IGN. Of course, we also discuss the latest NPD results. Spoiler alert: Sony's still ahead--but perhaps not by as much as it was before! Our intro music, of course, is the infamous "Troll Song," as the Internet has renamed it, in honor of Sony's and Microsoft's charming antics. If you want to hear it, search either "Troll Song" or "Trololol" on YouTube. You'll find it. The ending this week is "Shadow World," the theme from Persona 4 Golden. You can buy the P4, P4 Arena, and P4G soundtracks on Amazon (P4, P4A), CDJapan.co.jp (P4G), and other reputable Internet stores, but they are mainly sold as physical CDs and imported from Japan. All of this and more comprises the latest epsiode of RDGH. Tweet us @TheRDGH if you have something to say--we'll read it on the air. Enjoy, and don't be a racist.
After much delay and talking, The Persona Podcast is now Shin Megami Tensei Network. What does this mean for the podcast? Things will stay the same except there will no longer be as large of a focus on just Persona and now. While we were gone two great SMT games released for the 3DS and P4A has released worldwide (finally). Be sure to listen to find out even more. Also be sure to keep spreading the word so the podcast can keep growing. We wouldn't be where we are a year from when we started if it was not for all of you amazing listeners!
This week, nostalgia! New patchnotes for World of Warcraft bring back memories of the good old days, and raises the question; just what was so great about them anyway? Plus, The Secret World may not be as terrible as we thought, the end of the P4A tragedy is in sight, Final Fantasy failures and more. Have something to say? Send your emails to noexcusesvtw@gmail.com. Email question of the week: Tell us a story about your favourite MMO memory
The social links just keep getting stranger and stranger with the podcast this week. We spend a lot of time talking about some spoiler free thoughts on P4A as well as all the new P4G news that has been released. This week Melissa comes back, but sadly no Lauren since she was busy in the velvet room. So this means Will and Spencer will fill out the rest of the show with Melissa.
This week, Its the battle of the RPG's! Is the traditional JRPG as read as eveyone claims, or is the western RPG bland and repetitive? Plus, Blazblue! We've been playing it in the leadup to P4A, does it live up to the hype? Have something to say? Send your emails to noexcusesvtw@gmail.com. Question of the week: Tell us about your experiences with RPG's, Eastern and Western. Or, Played Blazblue? Tell us about it!
news, life, youtube videos, fun and more ..guest co-host Megan Chapman
© 2020-2025 Ivy Podcast Discovery LLC
